clopidogrel has been researched along with Alloxan Diabetes in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Y; Li, X; Shi, Q; Zhang, J | 1 |
| Chen, X; Gu, J; Guo, Y; Shan, Y; Sun, D; Wang, Y; Yao, H | 1 |
| Cai, Y; Chen, S; Du, C; Gao, Y; Lai, W; Qin, C; Yang, C; Zhou, J | 1 |
| Cai, L; Cheng, Y; Fu, Y; Gao, J; Gozal, E; Lian, X; Lu, X; Ma, T; Rane, MJ; Sun, W; Wang, W; Weng, W; Zheng, Z | 1 |
| Arrebola, M; De La Cruz, P; de la Cuesta, FS; González-Correa, A; Martinez-Cerdán, E; Moreno, A | 1 |
| Dagher, Z; Gerhardinger, C; Hoehn, T; Lorenzi, M; Sun, W | 1 |
6 other study(ies) available for clopidogrel and Alloxan Diabetes
| Article | Year |
|---|---|
Silibinin augments the effect of clopidogrel on atherosclerosis in diabetic ApoE deficiency mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Clopidogrel; Diabetes Mellitus, Experimental; Mice; Mice, Inbred C57BL; Mice, Knockout; Silybin | 2022 |
Type 2 diabetes mellitus decreases systemic exposure of clopidogrel active metabolite through upregulation of P-glycoprotein in rats.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Intestinal Absorption; Male; Microsomes, Liver; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Up-Regulation | 2020 |
Critical Role of P2Y
Topics: Adenosine; Animals; Autoimmune Diseases; Cell Differentiation; Cells, Cultured; Clopidogrel; Colitis; Diabetes Mellitus, Experimental; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Gene Expression Regulation; Interleukin-17; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Mice, Knockout; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Th17 Cells; Ticagrelor; Ticlopidine; Trinitrobenzenesulfonic Acid | 2017 |
Clopidogrel Reduces Fibronectin Accumulation and Improves Diabetes-Induced Renal Fibrosis.
Topics: Animals; Blood Coagulation; Blotting, Western; Clopidogrel; Diabetes Mellitus, Experimental; Fibronectins; Fibrosis; Immunohistochemistry; Kidney; Kidney Diseases; Male; Mice; Mice, Inbred C57BL; Purinergic P2Y Receptor Antagonists | 2019 |
Effects of clopidogrel and ticlopidine on experimental diabetic ischemic retinopathy in rats.
Topics: 6-Ketoprostaglandin F1 alpha; Administration, Oral; Animals; Clopidogrel; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dose-Response Relationship, Drug; Male; Nitrates; Nitric Oxide; Nitrites; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Retinal Vessels; Thromboxane B2; Ticlopidine | 2003 |
Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dinoprostone; Humans; Neurons; Platelet Aggregation Inhibitors; Rats; Retina; Retinal Vessels; Ticlopidine | 2005 |